Can infection-related molecular mimicry and inflammation break immune tolerance in neurologic disease?

Infection can, in selected postinfectious neurologic syndromes, initiate a self-directed immune response through microbial–host antigen resemblance and inflammatory amplification. This is biologically important, but neither prior infection nor antibody positivity alone identifies the cause of a person’s neurologic symptoms.

Clinical and mechanistic evidence

• Campylobacter jejuni–associated Guillain–Barré syndrome provides the clearest model: bacterial lipooligosaccharides mimic peripheral-nerve gangliosides, and anti-GM1, anti-GD1a, or anti-GQ1b antibodies can bind nerve targets, activate complement, and contribute to axonal injury. Inflammatory cytokine signaling (including IL-1β, IL-6, and TNF), Th17/Treg imbalance, and blood–nerve-barrier disruption may facilitate this process.
• Molecular mimicry can activate autoreactive B- and T-cell clones that escaped normal tolerance controls. However, cross-reactive antibody generation appears to require a multistep setting: a relevant mimicking antigen, antigen presentation and costimulation, persistence of autoreactive clones, and an inflammatory context.
• Additional functional evidence includes HTLV-1-associated myelopathy, in which patient IgG cross-reacting between HTLV-1 Tax and neuronal hnRNP-A1 entered neurons and inhibited firing ex vivo.

Interpretation of serology

• Infectious antibodies may persist long after infection clearance: Lyme IgG/IgM and even the CSF:serum Borrelia antibody index can remain positive for years to decades; other infection-associated IgG responses can persist for months to years.
• Neural antibody results likewise require phenotype-, assay-, titer-, and compartment-specific interpretation. Low-titer serum-only findings, especially with an atypical syndrome, carry meaningful false-positive risk.

Bottom line

• Molecular mimicry and infection-related inflammation are credible contributors to neurologic autoimmunity—most convincingly in defined syndromes such as post-Campylobacter GBS—but serologic reactivity alone does not establish active infection, pathogenic autoimmunity, or causation. Attribution requires a compatible syndrome, exposure and timing, and objective corroboration, ideally including paired serum/CSF or other disease-specific evidence.